Evaluating the efcacy and microenvironment changes of HER2+gastric cancer during HLX02 and Endostar treatment using quantitative MRI
Số trang: 11
Loại file: pdf
Dung lượng: 2.43 MB
Lượt xem: 13
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Trastuzumab is an important targeted drug for HER2-positive gastric cancer. The treatment efcacy of a more cost-efective and accessible trastuzumab biosimilar, HLX02, was not well investigated, especially when combined with antiangiogenic treatment.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Gastric cancer Vascular normalization Antiangiogenic treatment HER2-positive gastric cancerTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 175 0 0 -
6 trang 169 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 147 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 126 0 0 -
12 trang 98 0 0
-
19 trang 76 0 0
-
17 trang 68 0 0
-
9 trang 46 0 0
-
12 trang 40 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 39 0 0